Danish pharmacological company Genmab has declared, that the first results of the second phase of clinical testing of preparation Arzerra have passed successfully, transfers Reuters.
Experts prognosticate, that Arzerra becomes the first accessible effective medicine for a cancer. Genmab is engaged in product working out together with colleagues from GlaxoSmithKline.

The communique about success of tests Arzerra has appeared after nine days after hearings about a failure of the tests which have provoked a collapse of stocks Genmab. Company Securities had time to go down in cost approximately on 30 %.

"We are glad to inform on the positive takes shown during tests. The company believes, that it proves huge potential Arzerra in treatment sphere follicular lymphoma", - is spoken in the statement of president Genmab.

The positive effect gives a new medicine in a combination with such preparations, as cyclophosphamide, Prednisonum, Vincristinum and Doxorubicinum.
58 patients took part in experiment with the diagnosis follicular lymphoma. The indicator of reaction of organisms on a preparation has made from 90 % to 100 % depending on dose Arzerra, note in the company-manufacturer.

Thus any side effects of a preparation during tests, and also later 30 days after their end have not been taped.